===
EQS-News: MeVis Medical Solutions AG / Key word(s): Annual Results
MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024
2024-01-29 / 19:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
. Turnover down by EUR 1.5 million to EUR 17.3 million
. EBIT of EUR 3.9 million, 23% margin
. Earnings after taxes down by EUR 2.9 million to EUR 4.9 million
. Forecast for the 2023/2024 financial year
? Slight increase in sales from EUR 18.0 million to EUR 18.5 million
? EBIT stable at EUR 4.5 million to EUR 5.0 million


Bremen, January 29, 2024 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company,
announces its results for the fiscal year 2022/2023, with reporting period October 1, 2022 to September 30, 2023.
Revenue in the past financial year 2022/2023 amounted to EUR 17.3 million (compared to EUR 18.8 million in the financial
year 2021/2022). Of the revenue, 26 % (previous year: 28 %) is attributable to the sale of licenses, 36 % (previous
year: 32 %) to maintenance revenue and 38 % (previous year: 38 %) to other revenue, which includes services for and
recharges to affiliated companies and the parent company.
The decline in sales compared to the previous year is mainly due to the decline in the license business, but also to
the postponement of a development project, which we now expect to start in 2024. Other revenue, especially development
services, fell slightly, while maintenance revenue continued to develop very positively.
The results are still satisfactory in view of the development of sales. EBIT (earnings before interest and taxes) of EUR
3.9 million was generated in 2022/2023, compared to EUR 7.9 million in 2021/2022. The EBIT margin fell accordingly to 23
% compared to the previous year's figure of 42 %.
As a result of the fiscal unity, only low income taxes of EUR 0.1 million were incurred in the past financial year,
identical to the previous year.
This results in earnings after taxes of EUR 4.9 million (28% margin) for the 2022/2023 financial year, compared to EUR 7.8
million (41% margin) in 2021/2022. The profit of EUR 4,920 thousand will be transferred to Varex Imaging Deutschland AG
on the basis of the control and profit transfer agreement.
For the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between EUR 18.0 million
and EUR 18.5 million. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver
area are also expected to increase slightly. We expect a slight decline in the area of development services. For
earnings before interest and taxes (EBIT), we expect stability in the range of EUR 4.5 million to EUR 5.0 million. The
forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key
drivers for the EBIT outlook.
The half-year financial report for the 2023/2024 financial year will be published on May 27, 2024.

Contact:
Kirchhoff, Marcus / CEO
2024-01-29 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      MeVis Medical Solutions AG 

Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone:        +49 421 224 95 0 
Fax:          +49 421 224 95 999 
E-mail:       ir@mevis.de 
Internet:     http://www.mevis.de 
ISIN:         DE000A0LBFE4 
WKN:          A0LBFE 
Listed:       Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1825455

End of News EQS News Service
===
1825455 2024-01-29 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1825455&application_name=news

END) Dow Jones Newswires

January 29, 2024 13:00 ET (18:00 GMT)